A randomized, placebo-controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER)

Authors

Cary D Austin, Genentech, Inc.
Kaharu Sumino, Washington University School of Medicine in St. Louis
et al.

Journal

Clinical and experimental allergy

Publication Date

12-1-2020

Volume

50

Issue

12

First Page

1342

Last Page

1351

Document Type

Open Access Publication

DOI

10.1111/cea.13731

Rights and Permissions

Austin, CD, Gonzalez Edick, M, Ferrando, RE, et al; on behalf of the CLAVIER Investigators. A randomized, placebo-controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER). Clin. Exp. Allergy. 2020; 50: 1342– 1351. https://doi.org/10.1111/cea.13731 © 2020 The Authors. Clinical & Experimental Allergy published by John Wiley & Sons Ltd This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Recommended Citation

Austin, Cary D; Sumino, Kaharu; and et al., "A randomized, placebo-controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER)." Clinical and experimental allergy. 50, 12. 1342 - 1351. (2020).
https://digitalcommons.wustl.edu/oa_4/1793

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.